23 Dec 2023 • Tirzepatide demonstrated a significant and dose-dependent reduction in urine albumin-to-creatinine ratio in patients with type 2 diabetes mellitus.

The decrease in albuminuria was consistent across all doses (5, 10, and 15 mg), highlighting a dose-response relationship.

There was a neutral effect on the estimated glomerular filtration rate, indicating no adverse impact on renal function.

These findings suggest that tirzepatide probably leads to a significant reduction in albuminuria across all administered doses, while its use is associated with a neutral effect on creatinine clearance as a measure of renal function.

Source: Diabetes, Obesity & Medicine | Read full story